We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQVIA Holdings Inc. (IQV - Free Report) reported solid second-quarter 2022 results, wherein its earnings as well as revenues surpassed the Zacks Consensus Estimate.
Adjusted earnings per share (excluding $1.10 from non-recurring items) of $2.44 beat the consensus mark by 2.1% and improved 15% on a year-over-year basis. The reported figure is above the guided range of $2.35-$2.42.
Total revenues of $3.54 billion outpaced the consensus estimate by 1.2% and increased 3% year over year on a reported basis and 7.1% on a constant-currency basis. The reported figure lies above the guided range of $3.47-$3.52 billion.
Let’s check out the numbers in detail:
Segmental Revenues
Revenues from Technology & Analytics Solutions totaled $1.41 billion, up 4.1% on a reported basis and 9.4% on a constant-currency basis.
IQVIA Holdings Inc. Price, Consensus and EPS Surprise
Research & Development Solutions’ revenues of $1.95 billion increased 3.1% on a reported basis and 6% on a constant-currency basis.
Revenues from Contract Sales & Medical Solutions totaled $183 million, down 5.7% on a reported basis but up 2.1% on a constant-currency basis.
Operating Performance
Adjusted EBITDA was $800 million, up 10.8% year over year.
Balance Sheet and Cash Flow
IQVIA exited second-quarter 2022 with cash and cash equivalents balance of $1.43 billion compared with $1.39 billion at the end of the prior quarter. Long-term debt (less current portion) was $12.6 billion compared with $12.5 billion at the end of the prior quarter.
IQV generated $329 million of cash from operating activities in the reported quarter, while CapEx was $161 million. Free cash flow was $168 million.
During the reported quarter, IQVIA repurchased shares worth $590 million. As of Jun 30, 2022, IQVIA had $1.53 million of its share buyback authorization outstanding.
Third-Quarter 2022 Guidance
IQVIA expects third-quarter revenues in the range of $3.515-$3.565 billion. The current Zacks Consensus Estimate of $3.61 billion lies above the guidance.
Adjusted earnings per share are expected between $2.34 and $2.42. The Zacks Consensus Estimate of $2.48 lies above the guidance.
Adjusted EBITDA is anticipated between $805 million and $820 million.
2022 Guidance
For 2022, IQVIA’s expectation of low-to-mid teens organic revenue growth at constant currency, excluding COVID-related work, remains unchanged.
IQVIA now expects revenues between $14.40 billion and $14.55 billion compared with the prior guidance of $14.45-$14.75. The current Zacks Consensus Estimate of $14.57 billion lies above the updated guidance.
Adjusted earnings per share are expected between $10.00 and $10.20 (prior guidance: $9.95 and $10.25). The midpoint of the guided range ($10.10) lies below the current Zacks Consensus Estimate of $10.13.
Adjusted EBITDA is anticipated between $3.345 billion and $3.395 billion (prior guidance: from $3.330 billion to $3.405 billion). Currently, IQVIA carries a Zacks Rank #4 (Sell).
Investors interested in the broader Zacks Business Services sector can consider stocks like Cross Country Healthcare (CCRN - Free Report) , Waste Management (WM - Free Report) and Republic Services (RSG - Free Report) , which will report second-quarter 2022 numbers soon.
Cross Country Healthcare will release results on Aug 3. The stock has an expected earnings growth rate of 55.9% for the current year.
CCRN's shares have gained 89.7% in the past year. Cross Country Healthcare has a long-term earnings growth of 6.9%.
Waste Management will report quarterly numbers on Jul 27. The stock has an expected earnings growth rate of 14.7% for the current year.
WM’s shares have gained 5.4% in the past year. Waste Management has a long-term earnings growth of 10.9%.
Republic Services will report results on Aug 4. The stock has an expected earnings growth rate of 12% for the current year.
RSG’s shares have gained 12.4% in the past year. Republic Services has a long-term earnings growth of 10.5%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
IQVIA (IQV) Beats on Q2 Earnings & Revenues, Alters '22 View
IQVIA Holdings Inc. (IQV - Free Report) reported solid second-quarter 2022 results, wherein its earnings as well as revenues surpassed the Zacks Consensus Estimate.
Adjusted earnings per share (excluding $1.10 from non-recurring items) of $2.44 beat the consensus mark by 2.1% and improved 15% on a year-over-year basis. The reported figure is above the guided range of $2.35-$2.42.
Total revenues of $3.54 billion outpaced the consensus estimate by 1.2% and increased 3% year over year on a reported basis and 7.1% on a constant-currency basis. The reported figure lies above the guided range of $3.47-$3.52 billion.
Let’s check out the numbers in detail:
Segmental Revenues
Revenues from Technology & Analytics Solutions totaled $1.41 billion, up 4.1% on a reported basis and 9.4% on a constant-currency basis.
IQVIA Holdings Inc. Price, Consensus and EPS Surprise
IQVIA Holdings Inc. price-consensus-eps-surprise-chart | IQVIA Holdings Inc. Quote
Research & Development Solutions’ revenues of $1.95 billion increased 3.1% on a reported basis and 6% on a constant-currency basis.
Revenues from Contract Sales & Medical Solutions totaled $183 million, down 5.7% on a reported basis but up 2.1% on a constant-currency basis.
Operating Performance
Adjusted EBITDA was $800 million, up 10.8% year over year.
Balance Sheet and Cash Flow
IQVIA exited second-quarter 2022 with cash and cash equivalents balance of $1.43 billion compared with $1.39 billion at the end of the prior quarter. Long-term debt (less current portion) was $12.6 billion compared with $12.5 billion at the end of the prior quarter.
IQV generated $329 million of cash from operating activities in the reported quarter, while CapEx was $161 million. Free cash flow was $168 million.
During the reported quarter, IQVIA repurchased shares worth $590 million. As of Jun 30, 2022, IQVIA had $1.53 million of its share buyback authorization outstanding.
Third-Quarter 2022 Guidance
IQVIA expects third-quarter revenues in the range of $3.515-$3.565 billion. The current Zacks Consensus Estimate of $3.61 billion lies above the guidance.
Adjusted earnings per share are expected between $2.34 and $2.42. The Zacks Consensus Estimate of $2.48 lies above the guidance.
Adjusted EBITDA is anticipated between $805 million and $820 million.
2022 Guidance
For 2022, IQVIA’s expectation of low-to-mid teens organic revenue growth at constant currency, excluding COVID-related work, remains unchanged.
IQVIA now expects revenues between $14.40 billion and $14.55 billion compared with the prior guidance of $14.45-$14.75. The current Zacks Consensus Estimate of $14.57 billion lies above the updated guidance.
Adjusted earnings per share are expected between $10.00 and $10.20 (prior guidance: $9.95 and $10.25). The midpoint of the guided range ($10.10) lies below the current Zacks Consensus Estimate of $10.13.
Adjusted EBITDA is anticipated between $3.345 billion and $3.395 billion (prior guidance: from $3.330 billion to $3.405 billion). Currently, IQVIA carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Upcoming Releases
Investors interested in the broader Zacks Business Services sector can consider stocks like Cross Country Healthcare (CCRN - Free Report) , Waste Management (WM - Free Report) and Republic Services (RSG - Free Report) , which will report second-quarter 2022 numbers soon.
Cross Country Healthcare will release results on Aug 3. The stock has an expected earnings growth rate of 55.9% for the current year.
CCRN's shares have gained 89.7% in the past year. Cross Country Healthcare has a long-term earnings growth of 6.9%.
Waste Management will report quarterly numbers on Jul 27. The stock has an expected earnings growth rate of 14.7% for the current year.
WM’s shares have gained 5.4% in the past year. Waste Management has a long-term earnings growth of 10.9%.
Republic Services will report results on Aug 4. The stock has an expected earnings growth rate of 12% for the current year.
RSG’s shares have gained 12.4% in the past year. Republic Services has a long-term earnings growth of 10.5%.